PAWC
CLLS

P.A.W. Capital’s Cellectis CLLS Stock Holding History

P.A.W. Capital’s Portfolio CLLS Stock Details CLLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-40,000
Closed -$1.13M – 63
2018
Q3 		$1.13M Hold
40,000
– – 1.2% 27
2018
Q2 		$1.13M Buy
40,000
+26,500
+196% +$789K 1.14% 26
2018
Q1 		$425K Buy
+13,500
New +$426K 0.51% 56

Other funds holding CLLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

P.A.W. Capital's CLLS Position: Q4 2018 in Review

P.A.W. Capital sold out of Cellectis (CLLS) in Q4 2018, closing a stake of 40,000 shares — an estimated $1.13M sold.

P.A.W. Capital first reported a position in CLLS in Q1 2018 and held it in 3 quarters. The position peaked at $1.13M in Q2 2018. 65 funds tracked by Wall St. Rank hold CLLS as of Q4 2018.

  • P.A.W. Capital reported no remaining Cellectis position as of Q4 2018 after selling out during the quarter.
  • P.A.W. Capital sold 40,000 Cellectis shares in Q4 2018, an estimated $1.13M.
  • P.A.W. Capital first reported a position in Cellectis in Q1 2018 and held it in 3 quarters.
  • P.A.W. Capital's Cellectis position peaked at $1.13M in Q2 2018.
  • 65 funds tracked by Wall St. Rank held Cellectis as of Q4 2018.

Based on P.A.W. Capital's 13F filing for Q4 2018, filed 6 Feb 2019.